News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Conference News AHA 2024 One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024 Shelley Wood November 14, 2024
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2020 Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON Michael O'Riordan November 15, 2020
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
News Conference News AHA 2018 New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening Michael O'Riordan November 10, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News You Can’t Blame Your Genes: Healthy Lifestyle Halves Genetic Risk of CAD Shelley Wood November 15, 2016
News Conference News ACC 2016 Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH Michael O'Riordan April 03, 2016